CardioTech International, Inc. Announces Patent Filing for Antimicrobial Polymers Designed to Avoid Infections Without Using Antibiotic Drugs

WILMINGTON, Mass., June 18 /PRNewswire-FirstCall/ -- CardioTech International, Inc. , a developer and manufacturer of advanced materials and medical devices for the treatment of cardiovascular and other diseases, announced today that it has filed for a US patent on its proprietary antimicrobial formulation of ChronoFlex(R) medical grade polymer and its method of fabrication. These materials are designed to provide a new method for the medical device industry to better control foreign body-derived infections without the use of antibiotic drugs. Cardiotech's antimicrobials can be used in devices as a polymer or a coating.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070322/CLTH022LOGO )

Commenting on the patent filing, Andrew Reed, Ph.D., CardioTech's Vice President of Science & Technology, said: "With this patent filing, we have introduced a new antimicrobial family of ChronoFlex polymers. Current technology in the marketplace uses antibiotic drugs, which often become depleted in the body and can form antibiotic-resistant bacteria. Moreover, the antimicrobial component of these polymers has been designed to be non-leaching as a result of the polymerization process. Remaining as a component of the polymer is a vital factor for preventing infection."

President & CEO Michael Adams noted that, "Medical device infections cause 70,000 US deaths annually, costing our hospitals an estimated $9 billion. Our antimicrobial polymer technology received a great deal of attention at the Medical Design and Manufacturing -- East conference and exposition last week in New York City. The filing for a new patent reflects the increasing value of CardioTech's intellectual property and builds upon our strategy of developing world class advanced materials."

About CardioTech International:

CardioTech International, Inc. is a medical device company that designs, develops, manufactures and sells innovative products and materials for the treatment of cardiovascular, orthopedic, oncology, urology and other diseases. The Company's business model calls for leveraging its technological and manufacturing expertise in order to expand its royalty and license fee income, develop next generation polymers and manufacture new and complex medical devices. CardioTech is conducting its first clinical trial for regulatory approval in Europe for its CardioPass(TM) synthetic coronary bypass graft. The Company generates revenues from sales of advanced medical devices and materials, as well as from contracted product design and development services. More information about CardioTech is available at its website: http://www.cardiotech-inc.com.

Forward-Looking Statements:

CardioTech believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause results to differ materially from the forward-looking statements. For further information on such risks and uncertainties, you are encouraged to review CardioTech's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended March 31, 2006 and its Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2006, September 30, 2006 and December 31, 2006. CardioTech assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

For Further Information Contact: Eric Walters Vice President & Chief Financial Officer CardioTech International, Inc. 978-657-0075 general-info@cardiotech-inc.com Sylvia Dresner Senior Vice President VMW Corporate & Investor Relations 212-616-6161 info@vmwcom.com

Photo: http://www.newscom.com/cgi-bin/prnh/20070322/CLTH022LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCardioTech International, Inc.

CONTACT: Eric Walters, Vice President & Chief Financial Officer,CardioTech International, Inc., +1-978-657-0075,general-info@cardiotech-inc.com; or Sylvia Dresner, Senior Vice President,VMW Corporate & Investor Relations, +1-212-616-6161, info@vmwcom.com

Web site: http://www.cardiotech-inc.com/